Quick search:
Content Search
Result Content Research
Result Content Research
1 If You Invested $5,000 in Vertex Pharmaceuticals In 2016, This Is How Much You Would Have Today
2 Here's Why Vertex Pharmaceuticals (VRTX) is a Strong Value Stock
3 Vertex Pharmaceuticals Stock Is Likely To Rebound From $180 Levels Currently
4 Vertex reports positive results for first patient in Type 1 diabetes trial
5 Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day
6 'This is the time to double down': Top Vertex executives defend research plan as pressure builds
7 Why Are Investors Ignoring Vertex's Good News?
8 September Sell-Off Alert: Buy Vertex Pharmaceuticals on the Dip
9 Boston Biotech Vertex Struggles to Repeat Cystic Fibrosis Success
10 Vertex: Impressive early results for potentially curative diabetes cell therapy
11 Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day
12 Vertex Pharmaceuticals Inc. stock falls Monday, underperforms market
13 The Price Is Right For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
14 Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors
15 Should You Buy Vertex Pharmaceuticals Incorporated (VRTX) Stock Monday?
16 Vertex Pharmaceuticals Inc. stock rises Thursday, still underperforms market
17 Scientist behind Vertex CF drugs launches new startup, Rectify Pharmaceuticals, with Atlas Venture
18 Vertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors
19 Vertex Pharmaceuticals Inc. stock rises Wednesday, outperforms market
20 Vertex Pharmaceuticals Inc. stock falls Thursday, underperforms market
21 Vertex Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors despite daily gains
22 Vertex Pharmaceuticals Incorporated (VRTX) Stock Falls -1.51% This Week: Is It a Good Pick?
23 Vertex Pharmaceuticals Inc. stock falls Friday, underperforms market
24 Vertex Pharmaceuticals Inc. stock rises Tuesday, outperforms market
25 Vertex Pharmaceuticals Inc. stock falls Wednesday, underperforms market
26 Reasons To Buy Vertex Below $200
27 Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
28 Do Traders Think Vertex Pharmaceuticals Incorporated (VRTX) Can Turn Around Monday?
29 Vertex Pharmaceuticals Incorporated (VRTX) is lower by -2.13% in a Week, Should You Sell?
30 Should You Add Vertex Pharmaceuticals Incorporated (VRTX) Stock to Your Portfolio Wednesday?
31 Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know
32 Vertex Pharmaceuticals Inc. stock outperforms market despite losses on the day
33 Vertex Pharmaceuticals Inc. stock falls Monday, still outperforms market
34 In search of the next blockbuster
35 Vertex Pharmaceuticals Incorporated (VRTX) Stock: What Does the Chart Say Thursday?
36 Vertex's (VRTX) Early Type I Diabetes Study Data Promising
37 Vertex's Supplement to a New Drug Submission for KALYDECO® (ivacaftor) for Patients with Cystic Fibrosis Between the Ages of 4 Months and 18 Years with the R117H Mutation in the CFTR Gene Accepted for Priority Review by Health Canada
38 Vertex Pharmaceuticals (VRTX) Stock Moves -0.46%: What You Should Know
39 Vertex Pharmaceuticals (VRTX) Gains But Lags Market: What You Should Know
40 Zacks Value Investor Highlights: Nu Skin Enterprises, VF Corp, Yamana Gold, Meritor and Vertex Pharmaceuticals
41 2 Beaten-Down Growth Stocks to Buy Hand Over Fist
42 3 Big Pharma Stocks Wall Street Thinks Could Soar By At Least 30%
43 Democrat Kurt Schrader Keeps Raking in Pharma Bucks
44 3 Biotech Stocks Wall Street Thinks Could Rise 44% or Better
45 Is This Beaten Down Biotech a Bad News Buy?
46 Signature Wealth Management Pa
47 Should You Hold Vertex Pharmaceuticals Incorporated (VRTX) Stock Tuesday?
48 RBC Capital Stick to Their Buy Rating for Vertex Pharmaceuticals By
49 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Expected to Post Quarterly Sales of $1.85 Billion
50 Vertex to Present Long-Term Data Demonstrating Significant Benefits of Treatment With CFTR Modulators at North American Cystic Fibrosis Conference (NACFC)
51 3 Things About CRISPR Therapeutics That Smart Investors Know
52 SVB Leerink Comments on Vertex Pharmaceuticals Incorporated's FY2021 Earnings (NASDAQ:VRTX)
53 Vertex ends agreement with Molecular Templates for conditioning regimens
54 Is Now the Time to Ditch Pharma Stocks?
55 Letter of Intent Issued for Public Reimbursement of Trikafta in Canada
56 Vertex Pharma Reports 5 Scientific Abstracts About Co.'s Cystic Fibrosis Portfolio Will Be Presented At North American Cystic Fibrosis Conference Nov. 2-5, 2021
57 3 No-Brainer Stocks to Invest $500 In Right Now
58 3 No-Brainer Biotech Stocks to Buy Right Now
59 2 Stocks You'll Probably Never Want to Sell
60 3 Unstoppable Stocks to Buy in October
61 3 Highly Profitable Stocks Wall Street Thinks Will Soar 39% or More
62 Healthcare Still Looks Pricey
63 X4 Pharmaceuticals Expands Commercial Leadership Expertise with Appointment of Françoise de Craecker to Board of Directors and Karolyn Park as Vice President, U.S. Commercial
64 Vertex, (VRTX) falls 0.07% for October 15
65 Gene Editing Stocks Lag On Clinical Setbacks, Rising Yields. Time To Buy?
66 3 Top Healthcare Stocks to Buy for October
67 2 Healthcare Stocks You Can Buy and Hold for the Next Decade
68 VRTX vs. PRTA: Which Stock Should Value Investors Buy Now?
69 Inhibikase Therapeutics Announces Dosing of First Parkinson's Patient in its Phase 1b Clinical Trial of IkT-148009
70 Andrew Lo: It's Possible to Measure the Impact of Impact Investing
71 9 Meters Biopharma, Inc. Appoints Samantha Ventimiglia to Board of Directors
72 The Quest to Overcome Gene Therapy's Failures
73 3 Beaten-Down Stocks Cathie Wood Is Buying That Wall Street Thinks Will Skyrocket
74 Cystic Fibrosis Market 2021-2030 Detailed Analysis of Current and Future Industry Figures | Global Players – CHIESI Farmaceutici SpA, Demegen, Digestive Care, F. Hoffmann-La Roche – Puck77
75 Vertex Needs to Sell or Make a Big Acquisition
76 Peptide Based Infection Therapeutics Market 2021 Emerging Trends, Size, Share, Regional Outlook by 2028 | Gilead Sciences, Johnson & Johnson (janssen), Vertex Pharmaceuticals, Mitsubishi Tanabe Pharma – Puck77
77 5 Reasons to Buy Vertex Pharmaceuticals (VRTX) Stock Now
78 Can Vertex Pharmaceuticals Recover From Its Latest Setback?
79 Four Success Stories in Gene Therapy
80 3 Biotech Stocks That Could Make You Filthy Rich
81 2 Tricks and a Treat for Gene Therapy Investors
82 Rectify Nets $100 Million to Help the Body Relearn its ABCs
83 Why Vertex Pharmaceuticals Stock Is Getting Hammered Today
84 3 Stocks to Buy Without Any Hesitation If There's an October Stock Market Crash
85 Buying Vertex Pharmaceuticals Stock Now Could Double Your Money Within 5 Years: Here's How
86 2 Top Healthcare Stocks That Could Be Bought Out in 2022
87 Vertex, (VRTX) falls 0.82% on Strong Volume September 22
88 Could Vertex Pharmaceuticals Be a Prime Acquisition Target?
89 Calculating The Fair Value Of Vertex, Inc. (NASDAQ:VERX)
90 Global APOL1 Mediated Kidney Disease Market By Top Competitors 2021: Vertex Pharmaceuticals, Ionis Pharmaceuticals, Travere Therapeutics, ChemoCentryx
91 Analysis: Deals, data buzz could help biotech shares exit Wall St's 'no man's land'
92 Vertex's CF drugs drive 18% growth as company looks to diversify
93 Bull of the Day: Vertex Pharmaceuticals (VRTX)
94 If You Invested $3,000 in CRISPR Therapeutics in 2018, This Is How Much You Would Have Today
95 3 Things About Vertex Pharmaceuticals That Smart Investors Know
96 Other news to note for Oct. 18, 2021 | 2021-10-18
97 Despite Recent Underperformance, Institutions are Liking Vertex Pharmaceuticals (NASDAQ:VRTX)
98 2 Gene-Editing Stocks to Have on Your Radar Right Now
99 Adopting Continuous Manufacturing for Solid-Dose Drug Products
100 Why Cathie Wood Is Buying 2 Gene-Editing Stocks but Selling Another